Ratings ABL Bio Inc.

Equities

A298380

KR7298380007

End-of-day quote Korea S.E. Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
24,600 ^KRW	+2.29%		-1.60%	0.00%

25/03	Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	CI
2023	ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ABL BIO INC.	0.00%	875M	-	-
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B		B+
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B		B+
BIONTECH SE	-11.90%	22.41B		B+
ARGENX SE	+0.17%	22.28B		B
GENMAB A/S	-5.48%	19.07B		A-
WUXI APPTEC CO., LTD.	-37.36%	18B		A-
BEIGENE, LTD.	-5.17%	17.89B		B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B		C+
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes